Infant Heart Failure in Alström Syndrome: What to Know

Around 60% or more of children with Alström Syndrome develop dilated cardiomyopathy in infancy.¹ For many families, this is the first medical crisis and often the event that leads to the diagnosis. Infant cardiomyopathy in Alström is serious — it can cause severe heart failure — but it's also generally treatable, and most children recover their heart function with appropriate care. This article covers what infant cardiomyopathy looks like in Alström, how it's treated, and what to expect during recovery and long-term follow-up.

In dilated cardiomyopathy (DCM), the heart muscle becomes weaker and the chambers — especially the left ventricle — enlarge. The heart can't pump effectively, leading to congestive heart failure. Symptoms in babies include:

• Rapid breathing (tachypnea)
• Difficulty feeding (breathlessness during feeds)
• Sweating during feeds
• Poor weight gain or weight loss
• Pale or grayish skin, especially around the mouth
• Lethargy or reduced responsiveness
• Sometimes a heart murmur picked up by the pediatrician

In infants with Alström, dilated cardiomyopathy typically appears in the first few months of life — sometimes in the first weeks.²

The ALMS1 protein localizes to the basal body of primary cilia and to centrosomes. In heart muscle (cardiomyocytes), cilia and centrosomes play roles in development, organization, and signaling. When ALMS1 protein is missing or non-functional, heart-muscle cells appear to be vulnerable to dilated remodeling, particularly in early life.³

The exact mechanism — why infancy specifically, why some children with the same gene mutations develop cardiomyopathy and others don't — is incompletely understood. Research continues.

When a baby presents with signs of heart failure, the workup typically includes:

• Echocardiogram — ultrasound that visualizes the heart chambers, walls, and pumping function. The classic finding in Alström-related infant DCM is a dilated left ventricle with reduced ejection fraction.
• EKG — assesses heart rhythm and looks for arrhythmias
• Chest X-ray — looks at heart size and lung fluid
• Blood tests — including troponin, BNP (heart-failure marker), electrolytes, and metabolic panels
• Cardiac MRI — sometimes added later for more detail

If Alström is suspected because of accompanying eye signs or other features, genetic testing for ALMS1 and pediatric cardiomyopathy genes is ordered.⁴

Treatment of infant cardiomyopathy in Alström is similar to other forms of pediatric heart failure:

Standard medical therapy

• ACE inhibitors (captopril, enalapril) — reduce afterload and protect the heart muscle
• Diuretics (furosemide) — reduce fluid overload
• Beta-blockers (carvedilol) — once the baby is stabilized, beta-blockers protect the heart over time
• Digoxin — sometimes used to support contractility

Acute decompensation

For babies in severe heart failure or shock, ICU-level support may be needed:

• Intravenous inotropes (milrinone, dobutamine, epinephrine) to support heart function
• Mechanical ventilation if respiratory failure develops
• Mechanical circulatory support (ECMO, ventricular assist device) in extreme cases

Surgical options

In selected cases of severe infant DCM, surgical interventions including pulmonary artery banding have been used to alter the loading conditions of the failing heart.⁵ This is uncommon but described in the literature.

The natural history of infant DCM in Alström is generally encouraging:

• Most babies stabilize on standard heart-failure therapy over days to weeks
• Heart dimensions and function often improve substantially over weeks to months
• Many children's heart function appears normal on follow-up echo by mid-childhood
• Some children continue on maintenance heart medications for years
• A meaningful proportion have no residual cardiac disability after recovery⁶

Recovery doesn't mean the heart is permanently fixed — lifelong cardiac surveillance is recommended because a second wave of cardiomyopathy can appear in adolescence or adulthood.

After recovery from infant DCM, ongoing cardiology care is essential:

• Annual echocardiogram to monitor heart size and function
• Annual EKG
• Periodic cardiac MRI for more detail
• Continuation of heart medications as recommended by your cardiologist
• Vigilance for any new symptoms — fatigue, exercise intolerance, fluid retention, palpitations

The 2020 international consensus guidelines provide detailed surveillance recommendations.⁷

Parents whose babies have been through severe infant heart failure describe lasting effects:

• Heightened awareness of any cardiac symptom
• Anxiety about future events
• Difficulty fully relaxing about their child's wellbeing
• Posttraumatic responses for some

These reactions are common and worth talking through with a mental-health professional or peer support. Patient organizations connect families who've been through similar experiences.

Bring your child for urgent assessment if you notice:

• Significantly increased breathing rate
• Difficulty feeding or sweating with feeds
• Decreased activity or alertness
• Pale, gray, or bluish color
• Loss of weight or no weight gain over 2–3 weeks
• Vomiting or refusing feeds

Even after recovery from initial cardiomyopathy, these warrant evaluation.

• Could My Baby's Heart Failure Be Alström Syndrome?
• Restrictive Cardiomyopathy in Adolescents and Adults With Alström
• Heart Medications for Alström Syndrome
• Cardiac Monitoring Schedule for Alström Syndrome
• Heart Transplant in Alström Syndrome

April 30, 2026.